"Once NAbs have developed, the bioavailability of IFN beta as measured by MxA is completely inhibited."

-- Deisenhammer F, et al., Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-43

"RRMS patients with higher mean NK cell FA may be not only at greater risk for the development of active lesions but also may be more likely to respond to IFN-b. Development of neutralizing antibodies to IFN-b could interfere with this effect."

-- Kastrukoff LF, et al., Natural killer cells in relapsing-remitting MS: Effect of treatment with interferon b-1B. Neurology 1999;52:351-9

Welcome to a discussion on Recent Literature on the Role of NAbs in Patients Treated with Interferon Therapies

If you did not receive the NeuroCAST email two weeks ago, we recommend that you view Sessions I, II, and III prior to reviewing Session IV.

Begin Session IV
Next